Venture Capital Jobs and Internships at Aditum Bio

Aditum Bio brings together unmatched scientific and domain expertise with agile operational capabilities. Our unique investment and operating model enables rapid company formation, planning, and execution to advance novel drug candidates into the clinic and speed their delivery to the patients in need. 

PROVEN INDUSTRY LEADERSHIP AND SCIENTIFIC EXPERTISE

Launched by former Novartis CEO, Joe Jimenez, and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the experience of our founding executive team provides Aditum Bio with a unique lens for identifying and selecting innovative drug candidates with unrecognized potential.

BETTER OUTCOMES FOR PATIENTS. FASTER RETURNS FOR INVESTORS.

By singularly focusing on the translation phase of drug development, Aditum Bio efficiently identifies and develops potentially first- and best-in-class therapies for a broad array of diseases – empowering our ability to reach more patients and creating faster return for its capital investments.

OUR VALUES: ROOTED IN SCIENCE, INSPIRED BY PATIENTS

Aditum Bio is a new breed of biotech investment firm that is driven to translate science into the new medicines that make a meaningful difference in the lives of patients. We are a dedicated and ambitious team that is tightly aligned by a set of core values that underscore the important work we do.

WE ARE PATIENT CENTRIC

We have a passion to help patients, and this drives our decision making. We believe that our role is to develop therapies for patients with disorders currently neglected but which are scientifically tractable.

WE ARE COLLABORATIVE

We believe that we can accomplish more as a team than we can as individuals. We are respectful of each other and listen to understand. We enjoy fierce debate among ourselves to get to the right decision, but in a way that is respectful and appreciative. We pick our colleagues up when they are down.

WE ARE CURIOUS

We are a collection of people with high learning agility, and believe that no matter what age, we all have much to learn. We change our opinion without hesitation or embarrassment when new facts arise. We seek out the best experts in the world as advisors.

WE ARE COURAGEOUS

We define the single most important question to a new therapy’s success, then have the courage to answer it. We have a high emotional need to take on challenges and deliver results. We believe it is better to act on 80% of an answer than wait for the remaining 20%. We have the courage to stand up for our beliefs, but the humbleness to consider other viewpoints.

FULLFILLING THE PROMISE OF SCIENCE

Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense. Aditum Bio stands apart in the biotech venture capital arena through our differentiated approach for identifying promising, clinic-ready therapies that offer value for underserved patient populations, in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases.

ACCELERATING BIOTECH COMPANY FORMATION

Harnessing our experienced in-house R&D domain experts as the foundation of our agile operating model, Aditum Bio is able to accelerate the formation and ramp-up of its portfolio companies. We augment each company's newly-established, dedicated leadership team with medical and scientific experts. Operating under the Aditum Bio umbrella in a lean and efficient management structure, portfolio companies are empowered to rapidly progress newly-acquired drug candidates into Phase 2 clinical trials. 

LEVERAGING TECHNOLOGY FOR EFFICIENT TRIAL EXECUTION

Aditum Bio’s strategic advantage extends to its proven acumen for using an array of powerful technologies and digital tools throughout its portfolio companies to support clinical trial execution at the highest level of efficiency. Through our in-house technology capabilities and our extensive partnerships with leading solutions providers, we enable therapies to advance more quickly and at lower cost than in traditional R&D models.